跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 2,837 条关于
“KTX-0141”
全部
2,837
临床试验
1,520
药物
1,177
机构
6
资讯
134
3天前
Kasvu Therapeutics Raises €30M to Advance Non-Hallucinogenic TrkB-Targeting Depression Drug KTX-0141
4年前
K36 Therapeutics Receives FDA Clearance for First-in-Class Multiple Myeloma Drug KTX-1001
去年
Bristol-Myers Squibb Advances Two Multiple Myeloma Trials with Novel Drug Combinations
2年前
Ipilimumab/Nivolumab Combo Improves Survival in Non-Clear Cell Renal Cell Carcinoma
9个月前
First-in-Class MMSET Inhibitor Gintemetostat Shows Clinical Activity in Heavily Pretreated Multiple Myeloma
5个月前
Alethio Therapeutics Unveils ATX-011, First-in-Class Mutation-Agnostic Antibody for Essential Thrombocythemia Treatment
去年
Accent Therapeutics to Showcase Novel Cancer Therapeutics ATX-559 and ATX-295 at AACR 2025
2年前
Vasa Therapeutics' VS-041 Enters Clinical Trials for HFpEF Treatment
11个月前
Accent Therapeutics Unveils Promising Preclinical Data for Novel Cancer Therapies ATX-295 and ATX-559 at Major Oncology Conference
上个月
Surrozen Submits IND for SZN-8141, a Bifunctional Wnt Agonist/VEGF Antagonist for Diabetic Macular Edema
第 1 页,共 14 页
上一页
下一页